Patents Assigned to Shire Laboratories, Inc.
-
Patent number: 6361796Abstract: Disclosed is an osmotic pharmaceutical delivery system comprising (a) a semi-permeable wall that maintains its integrity during pharmaceutical delivery and which has at least one passage therethrough; (b) a single, homogeneous composition within said wall, which composition consists essentially of (i) a pharmaceutically active agent, (ii) at least one non-swelling solubilizing agent which enhances the solubility of the pharmaceutically active agent; (iii) at least one non-swelling osmotic agent and (iv) a non-swelling wicking agent dispersed throughout the composition which enhances the surface area contact of the pharmaceutical agent with the incoming aqueous fluid.Type: GrantFiled: August 9, 2000Date of Patent: March 26, 2002Assignee: Shire Laboratories, Inc.Inventors: Edward M. Rudnic, Beth A. Burnside, Henry H. Flanner, Sandra E. Wassink, Richard A. Couch, Jill E. Pinkett
-
Patent number: 6322819Abstract: A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.Type: GrantFiled: October 21, 1998Date of Patent: November 27, 2001Assignee: Shire Laboratories, Inc.Inventors: Beth A. Burnside, Xiaodi Guo, Kimberly Fiske, Richard A. Couch, Donald J. Treacy, Rong-Kun Chang, Charlotte McGuinness, Edward M. Rudnic
-
Patent number: 6287599Abstract: A pharmaceutical composition comprising at least one pharmaceutically active agent that is pH dependent, at least one non-pH dependent sustained release agent, and at least one pH dependent agent that increases the dissolution rate of the at least one pharmaceutically active agent at a pH in excess of 5.5. Such compositions have minimized pH-dependent dissolution profiles or pH-independent dissolution profiles.Type: GrantFiled: December 20, 2000Date of Patent: September 11, 2001Assignee: Shire Laboratories, Inc.Inventors: Beth A. Burnside, Rong-Kun Chang, Xiaodi Guo
-
Patent number: 6284276Abstract: Disclosed is an osmotic pharmaceutical delivery system comprising (a) a semipermeable wall that maintains its integrity during pharmaceutical delivery and which has at least one passage therethrough; (b) a single, homogeneous composition within said wall, which composition consists essentially of (i) a pharmaceutically active agent, (ii) at least one non-swelling solubilizing agent which enhances the solubility of the pharmaceutically active agent; (iii) at least one non-swelling osmotic agent and (iv) a non-swelling wicking agent dispersed throughout the composition which enhances the surface area contact of the pharmaceutical agent with the incoming aqueous fluid.Type: GrantFiled: July 11, 2000Date of Patent: September 4, 2001Assignee: Shire Laboratories, Inc.Inventors: Edward M. Rudnic, Beth A. Burnside, Henry H. Flanner, Sandra E. Wassink, Richard A. Couch, Jill E. Pinkett
-
Patent number: 6110498Abstract: An osmotic drug delivery system, preferably in tablet form, which dispenses a therapeutic agent having limited water solubility in solubilized form. The delivery system comprises a core that is free of swellable polymers and comprises nonswelling solubilizing agents and wicking agents. The solubilized therapeutic agent is delivered through a passageway in the semipermeable coating of the tablet.Type: GrantFiled: October 22, 1997Date of Patent: August 29, 2000Assignee: Shire Laboratories, Inc.Inventors: Edward M. Rudnic, Beth A. Burnside, Henry H. Flanner, Sandra E. Wassink, Richard A. Couch, Jill E. Pinkett
-
Patent number: 5952004Abstract: A pharmaceutical preparation comprising a stable, surface-active emulsion or dispersion of a pharmaceutical agent incorporated into an emulsion (i) having a hydrophobic discontinuous phase of a long chain carboxylic acid or ester or alcohol thereof dispersed in an aqueous phase or (ii) having a hydrophilic discontinuous phase dispersed in a hydrophobic phase of a long chain carboxylic acid or alcohol thereof. The emulsion with pharmaceutical agent is incorporated into a pharmaceutical carrier suitable for oral delivery.Type: GrantFiled: August 28, 1995Date of Patent: September 14, 1999Assignee: Shire Laboratories Inc.Inventors: Edward Rudnic, John McCarty, Beth Burnside, Charlotte McGuinness, George Belenduik
-
Patent number: 5948407Abstract: Disclosed is a method for reducing an immune response to a parenterally administered non-autologous antigen in an individual who is immunologically responsive thereto by mucosally administering to the individual an amount of the antigen effective to reduce any immune response to parenteral administration of said antigen. The antigen can be a polypeptide such as a hormone, like insulin, which supplements a metabolic deficiency in the recipient of a polypeptide intended to serve the same function. The polypeptide can also be one which supplements a deficiency in the production of a physiologically important polypeptide, such as a hematologic regulatory factor. The hematologic regulatory factor can enhance or inhibit thrombogenesis or platelet deposition. Also, the antigen can be a tissue or cell preparation, such as of allogeneic or xenogeneic tissue or cells.Type: GrantFiled: March 18, 1998Date of Patent: September 7, 1999Assignee: Shire Laboratories Inc.Inventors: Charlotte M. McGuinness, Beth A. Burnside, Edward M. Rudnik
-
Patent number: 5912013Abstract: The present invention relates to a composition and method of treating a patient by administering carbamazepine in a pharmaceutical dosage form capable of maintaining the patient's blood concentration at from about 4 .mu.g/ml to about 12 .mu.g/ml over at least a 12 hour period, where the blood concentration of carbamazepine does not vary by more than 60 percent.Type: GrantFiled: April 21, 1995Date of Patent: June 15, 1999Assignee: Shire Laboratories, Inc.Inventors: Edward M. Rudnic, George W. Belendiuk, John McCarty, Sandra Wassink, Richard A. Couch
-
Patent number: 5897876Abstract: A pharmaceutical preparation comprising a stable, surface-active emulsion or dispersion of a pharmaceutical agent incorporated into an emulsion (i) having a hydrophobic discontinuous phase of a long chain carboxylic acid or ester or alcohol thereof dispersed in an aqueous phase or (ii) having a hydrophilic discontinuous phase dispersed in a hydrophobic phase of a long chain carboxylic acid or alcohol thereof. The emulsion with pharmaceutical agent is incorporated into a pharmaceutical carrier suitable for oral delivery.Type: GrantFiled: June 20, 1997Date of Patent: April 27, 1999Assignee: Shire Laboratories Inc.Inventors: Edward M. Rudnic, John A. McCarty, George W. Belendiuk, deceased, Beth A. Burnside, Charlotte M. McGuinness, Krystyna Belendiuk
-
Patent number: 5883103Abstract: A pharmaceutical preparation for oral acyclovir delivery comprising a stable, hydrophobic emulsion comprising continuous phase of a hydrophobic material selected from the group consisting of a long chain carboxylic acid or ester or alcohol thereof dispersed in an aqueous phase or (ii) having a hydrophilic discontinuous phase dispersed in a hydrophobic phase of a long chain carboxylic acid or alcohol thereof. The emulsion with acyclovir is incorporated into a pharmaceutical carrier suitable for oral delivery.Type: GrantFiled: June 7, 1995Date of Patent: March 16, 1999Assignee: Shire Laboratories Inc.Inventors: Beth A. Burnside, Carol E. Mattes, Charlotte M. McGuinness, Edward M. Rudnic, George W. Belendiuk
-
Patent number: 5824638Abstract: A pharmaceutical preparation for oral insulin delivery comprising a stable, hydrophobic emulsion comprising continuous phase of a hydrophobic material selected from the group consisting of a long chain carboxylic acid or ester or alcohol thereof dispersed in an aqueous phase or (ii) having a hydrophilic discontinuous phase dispersed in a hydrophobic phase of a long chain carboxylic acid or alcohol thereof. The emulsion with insulin is incorporated into a pharmaceutical carrier suitable for oral delivery.Type: GrantFiled: May 22, 1995Date of Patent: October 20, 1998Assignee: Shire Laboratories, Inc.Inventors: Beth A. Burnside, Carol E. Mattes, Charlotte M. McGuinness, Edward M. Rudnic, George W. Belendiuk, deceased